
Shares of drugmaker Eli Lilly LLY.N rise 3.2% to $681.39 in afternoon trade
Lilly has signed a deal worth $1.3 billion with privately held Superluminal Medicines to discover and develop small-molecule drugs through AI to treat obesity and other cardiometabolic diseases
Boston-based startup Superluminal to receive payments, equity investment, royalties
Superluminal is backed by investors including RA Capital Management, Insight Partners and NVentures, NVIDIA's venture capital arm
Separately, Tiger Global Management raises share stake in Lilly by 13.2% to 1.5 million shares
Including session's moves, stock down 11.8% YTD